Summit Therapeutics PLC - Asset Resilience Ratio
Summit Therapeutics PLC (SMMT) has an Asset Resilience Ratio of 36.07% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Summit Therapeutics PLC (SMMT) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Summit Therapeutics PLC's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see SMMT total asset value.
Liquid Assets Composition Over Time
This chart breaks down Summit Therapeutics PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read SMMT liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $271.31 Million | 36.07% |
| Total Liquid Assets | $271.31 Million | 36.07% |
Asset Resilience Insights
- Very High Liquidity: Summit Therapeutics PLC maintains exceptional liquid asset reserves at 36.07% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Summit Therapeutics PLC Industry Peers by Asset Resilience Ratio
Compare Summit Therapeutics PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Summit Therapeutics PLC (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Summit Therapeutics PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 64.99% | $362.31 Million | $557.50 Million | -5.61pp |
| 2024-12-31 | 70.60% | $245.71 Million | $348.05 Million | +14.02pp |
| 2023-12-31 | 56.57% | $90.86 Million | $160.60 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $541.43 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $79.53 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $76.38 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $46.98 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $35.71 Million | -- |
| 2005-12-31 | 80.01% | $20.70 Million | $25.87 Million | +3.01pp |
| 2004-12-31 | 77.00% | $20.70 Million | $26.88 Million | -- |
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cance… Read more